Palisade Bio (PALI) Other Non-Current Assets (2010 - 2026)
Palisade Bio (PALI) posted quarterly Other Non-Current Assets of $17000.0 for Q1 2026, down 92.34% year-over-year from $222000.0 in Q1 2025, and down 69.09% quarter-over-quarter from $55000.0 in Q4 2025.
Palisade Bio (PALI) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Other Non-Current Assets for 17 consecutive years, with $17000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 92.34% year-over-year to $17000.0; the TTM figure through Mar 2026 stood at $17000.0 (down 92.34% YoY), while the FY2025 annual figure was $55000.0, down 79.85% from the prior year.
- Other Non-Current Assets slipped to $17000.0 in Q1 2026 per PALI's latest filing, from $55000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $592000.0 in Q2 2023 and bottomed at $12000.0 in Q3 2022.
- Historically, Other Non-Current Assets has averaged $150882.4 across 5 years, with a median of $26000.0 in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets slumped 96.98% — and 2023, when it surged 3550.0%.
- Palisade Bio's Other Non-Current Assets stood at $26000.0 in 2022, then tumbled by 53.85% to $12000.0 in 2023, then jumped by 2175.0% to $273000.0 in 2024, then slumped by 79.85% to $55000.0 in 2025, then slumped by 69.09% to $17000.0 in 2026.
- Business Quant data shows PALI's Other Non-Current Assets at $17000.0 in Q1 2026, $55000.0 in Q4 2025, and $119000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Palisade Bio | 372.94 Mn | 247.74 Mn | - | 55,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55,000.00 |
| Mar 31, 2026 | 17,000.00 |
| Dec 31, 2025 | 55,000.00 |
| Sep 30, 2025 | 119,000.00 |
| Jun 30, 2025 | 12,000.00 |
| Mar 31, 2025 | 222,000.00 |
| Dec 31, 2024 | 273,000.00 |
| Sep 30, 2024 | 324,000.00 |
| Jun 30, 2024 | 387,000.00 |
| Mar 31, 2024 | 12,000.00 |
| Dec 31, 2023 | 12,000.00 |
| Sep 30, 2023 | 438,000.00 |
| Jun 30, 2023 | 592,000.00 |
| Mar 31, 2023 | 12,000.00 |
| Dec 31, 2022 | 26,000.00 |
| Sep 30, 2022 | 12,000.00 |
| Jun 30, 2022 | 26,000.00 |
| Mar 31, 2022 | 26,000.00 |
| Dec 31, 2021 | 26,000.00 |
| Sep 30, 2021 | 26,000.00 |